Reducing suboptimal prescribing of glucagon-like peptide mimetics in type 2 diabetes

In 2016, spend on diabetes prescribing  — and glucagon-like peptide 1 (GLP-1) mimetics, in particular — at NHS Hastings and Rother Clinical Commissioning Group (CCG) and NHS Eastbourne, Hailsham and Seaford CCG was significantly higher than expected, based on national prescribing patterns. There was also significant variation betwee n GP practices. A project was undertaken by the medicines management (MM) team to support primary care diabetes teams to work with patients to optimise prescribing ...
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research